Bioavailability of Naloxegol Formulations in Healthy Subjects

Phase 1, randomised, open-label trial of naloxegol in opioid-induced constipation (OIC) (4 arms), sponsored by AstraZeneca. Primary endpoints: Area Under Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity at 72 hours, Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration at 72 hours and 1 more. Started May 2015; status: completed.